Tedaviye Direçli Şizofrenide Psikofarmakolojik Yaklaşımlar
Özet
Şizofreni, sanrılar, halüsinasyonlar ve bilişsel bozukluklarla karakterize, kronik seyirli ve yüksek yetiyitimiyle giden önemli bir mental hastalıktır. Hastaların yaklaşık %30’u, en az iki farklı antipsikotiğin 6 hafta süreyle yeterli dozda kullanılmasına rağmen semptomların düzelmediği "tedaviye dirençli şizofreni" (TDŞ) grubunda yer almaktadır. TDŞ tanısı koymadan önce tedaviye uyumsuzluk, alkol-madde kullanımı, komorbiditeler ve çevresel stresörler mutlaka dışlanmalıdır. Farmakolojik yaklaşım olarak klinikte mevcut antipsikotiğin dozunu artırmak sık denense de bu stratejinin ek fayda sağladığına dair kanıtlar sınırlıdır. Bu süreçte FDA onaylı tek ilaç olan klozapin, TDŞ tedavisinde altın standart olarak kabul edilmektedir ve direnç kriterleri karşılanır karşılanmaz klozapine geçilmesi geciktirilmemelidir. Klozapin monoterapisine yanıt alınamayan ultra dirençli vakalarda ise diğer antipsikotiklerle kombinasyonlar, lamotrijin veya östradiol gibi ajanların eklenmesi ya da elektrokonvulsif tedavi (EKT) gibi güçlendirme seçenekleri değerlendirilmektedir.
Schizophrenia is a significant mental illness characterized by delusions, hallucinations, and cognitive impairments, presenting a chronic course and high disability. Approximately 30% of patients fall into the "treatment-resistant schizophrenia" (TRS) category, where symptoms fail to improve despite the use of at least two different antipsychotics at adequate doses for 6 weeks. Before diagnosing TRS, treatment non-adherence, alcohol or substance abuse, comorbidities, and environmental stressors must be strictly excluded. Although increasing the dose of the current antipsychotic is frequently attempted as a pharmacological approach in clinical practice, evidence supporting the additional benefit of this strategy remains limited. In this process, clozapine, the only FDA-approved drug, is recognized as the gold standard in the treatment of TRS, and switching to clozapine should not be delayed once resistance criteria are met. In ultra-resistant cases that fail to respond to clozapine monotherapy, augmentation strategies such as combinations with other antipsychotics, the addition of agents like lamotrigine or estradiol, or electroconvulsive therapy (ECT) are considered.
Referanslar
Juarez-Reyes MG, Shumway M, Battle C, Bacchetti P, Hansen MS, Hargreaves WA. Effects of stringent criteria on eligibility for clozapine among public mental health clients. Psychiatr Serv. 1995;46(8):801–6.
Essock SM, Hargreaves WA, Dohm F-A, Goethe J, Carver L HL. No Title. Clozapine eligibility among state Hosp patientsSchizophr Bull. 1996;22:15–25.
Elkis H. Treatment-Resistant Schizophrenia. Psychiatr Clin North Am. 2007 Sep 1;30(3):511–33.
Lehman AF, Lieberman JA, Dixon LB et al. AJP. No Title. Pract Guidel Treat patients with Schizophr Second Ed. 2004;161:1–56.
Leucht S, Cipriani A, Spineli L, Mavridis D, Örey D, Richter F, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet. 2013 Sep 14;382(9896):951–62.
Novick D, Haro JM, Suarez D, Vieta E, Naber D. Recovery in the outpatient setting: 36-month results from the Schizophrenia Outpatients Health Outcomes (SOHO) study. Schizophr Res. 2009 Mar 1;108(1–3):223–30.
Mamo DC. Managing Suicidality in Schizophrenia. 2007;52(June):59–70.
Kane J, Honigfeld G, Singer J, Meltzer H. Clozapine for the Treatment-Resistant Schizophrenic. 2013;11004.
Kennedy JL, Altar CA, Taylor DL, Degtiar I, Hornberger JC. The social and economic burden of treatment-resistant schizophrenia : a systematic literature review. 2012;63–76.
Lindenmayer J-P. Treatment refractory schizophrenia. Psychiatr Q. :2000;71:373–84,.
Psikiyatride Güncel - Tedaviye Dirençli Sizofreni Cilt: 5 Sayı:4;8-10. 2015. Ö. Böke. 2015;cilt 5:2015;265–8.
Conley RR, Buchanan RW. Evaluation of treatment-resistant schizophrenia. Schizophrenia Bulletin. 1997; 663–74.
McNabb CB, Tait RJ, McIlwain ME, Anderson VM, Suckling J, Kydd RR, et al. Functional network dysconnectivity as a biomarker of treatment resistance in schizophrenia. Schizophr Res. 2018 May 1;195:160–7.
Andreasen NC, Carpenter WT, Kane JM, Lasser RA, Marder SR, Weinberger DR. Remission in schizophrenia: Proposed criteria and rationale for consensus. American Journal of Psychiatry. 2005; 441–9.
Suzuki T, Remington G, Mulsant BH, Uchida H, Rajji TK, Graff-Guerrero A, et al. Defining treatment-resistant schizophrenia and response to antipsychotics: A review and recommendation. Psychiatry Res. 2012 May 15;197(1–2):1–6.
Agid O, Board A, Johnson CJ, Lilly E, Company US, Canada EL. Europe PMC Funders Group Europe PMC Funders Author Manuscripts Europe PMC Funders Author Manuscripts Treatment resistant schizophrenia : Treatment Response and Resistance in Psychosis ( TRRIP ) working group consensus guidelines on diagnosis and terminolo. 2018;174(666):216–29.
Kuipers E, Yesufu-udechuku A. Management of psychosis and schizophrenia in adults : summary of updated NICE guidance. 2014;1173(February):10–3.
Citrome L, Volavka J. Optimal Dosing of Atypical Antipsychotics in Adults : A Review of the Current Evidence. 2002;280–91.
Shimomura Y, Kikuchi Y, Suzuki T, Uchida H, Mimura M. Antipsychotic treatment strategies for acute phase and treatment resistance in schizophrenia : A systematic review of the guidelines and algorithms. Schizophr Res [Internet]. 2021;236(September):142–55. Available from: https://doi.org/10.1016/j.schres.2021.07.040
Grover S, Chakrabarti S, Kulhara P, Avasthi A. Clinical Practice Guidelines for Management of Schizophrenia. Indian J Psychiatry. 2017;59(Suppl 1):S19-S33. doi:10.4103/0019-5545.196972.
Meltzer HY, Bobo W, Roy A, et al. A randomized double blind comparison of clozapine and high dose olanzapine in treatment resistant patients with schizophrenia. J Clin Psychiatry. 2008;69:274–285.
Volavka J, Cooper TB, Czobor P, Lindenmayer JP, Citrome LL, Mohr P, Bark N. High-dose treatment with haloperidol: The effect of dose reduction. J Clin Psychopharmacol 2000; 20: 252–256.
Kelly DL, Richardson CM, Yu Y, Conley RR. Plasma concentrations of high-dose olanzapine in a double-blind crossover study. 2006;(July):393–8.
Moore TA, Buchanan RW, Buckley PF, Chiles JA, Conley RR, Crismon ML, et al. The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2006 update. J Clin Psychiatry. 2007;68:1751-62.
Lehman AF, Kreyenbuhl J, Buchanan RW, Dickerson FB, Dixon LB, Goldberg R, et al. The Schizophrenia Patient Outcomes Research Team (PORT): updated treatment recommendations 2003. Schizophr Bull. 2004;30:193-217.
Lewis W, Barnes TRE, Davies L, Murray RM, Dunn G, Hayhurst KP, et al. Randomized Controlled Trial of Effect of Prescription of Clozapine Versus Other Second-Generation Antipsychotic Drugs in Resistant Schizophrenia. 2006;32(4):715–23.
Mcevoy JP, Lieberman JA, Stroup TS, Davis SM, Meltzer HY, Rosenheck RA, et al. Effectiveness of Clozapine Versus Olanzapine , Quetiapine , and Risperidone in Patients With Chronic Schizophrenia Who Did Not Respond to Prior Atypical Antipsychotic Treatment. 2006;(April):600–10.
Tabak Ö, Durak R. Delayed initiation of clozapine may be related to poor response in treatment-resistant schizophrenia Alp Üçok , U ğ ur Ç ı kr ı kç ı l ı , Sercan Karabulut , Ada Salaj , Meliha Öztürk ,. 2015;290–5.
Taylor DM, Young C, Paton C. Prior antipsychotic prescribing in patients currently receiving clozapine: a case note review. J Clin Psychiatry. 2003;64:30-4.
Nielsen J, Damkier P, Lublin H, Taylor D. Optimizing clozapine treatment. Acta Psychiatr Scand. 2011;123(6):411–22.
Siskind D, Siskind V, Kisely S. Clozapine Response Rates among People with Treatment-Resistant Schizophrenia: Data from a Systematic Review and Meta-Analysis. Can J Psychiatry. 2017;62(11):772–7.
Miyamoto S, Fredrik Jarskog L, Wolfgang Fleischhacker W. New therapeutic approaches for treatment-resistant schizophrenia: A look to the future. J Psychiatr Res. 2014 Nov 1;58:1–6.
Howes OD, Vergunst F, Gee S, Mcguire P, Kapur S, Taylor D. Adherence to treatment guidelines in clinical practice : study of antipsychotic treatment prior to clozapine initiation {. 2012;481–5.
Porcelli S, Serretti A, Bianchini O. Clozapine augmentation with amisulpride. J Psychiatry Neurosci. 2014;39:E38-9.
Karunakaran K, Tungaraza TE, Harborne GC. Is clozapine-aripiprazole combination a useful regime in the management of treatment-resistant schizophrenia? J Psychopharmacol. 2007;21(4):453–6.
Barbui C, Signoretti A, Mule S, Boso M, Cipriani A. Does the addition of a second antipsychotic drug improve clozapine treatment? Schizophr Bull. 2009;35(2):458–68.
Basan A, Kissling W, Leucht S. Valproate as an adjunct to antipsychotics for schizophrenia: a systematic review of randomized trials. Schizophr Res. 2004 Sep 1;70(1):33–7.
Leucht, S.; McGrath, J.; White, P.; Kissling, W. Carbamazepine augmentation for schizophrenia: how good is the evidence?J. Clin. Psychiatry, 2002, 63, 218.
Zoccali R, Muscatello MR, Bruno A, Cambria R, Micò U, Spina E, et al. The effect of lamotrigine augmentation of clozapine in a sample of treatment-resistant schizophrenic patients: A double-blind, placebo-controlled study. Schizophr Res. 2007 Jul 1;93(1–3):109–16.
Tiihonen J, Wahlbeck K, Kiviniemi V. The efficacy of lamotrigine in clozapine-resistant schizophrenia: A systematic review and meta-analysis. Schizophr Res. 2009 Apr 1;109(1–3):10–4.
Kulkarni J, Gavrilidis E, Wang W, Worsley R, Fitzgerald PB, Gurvich C, et al. Estradiol for treatment-resistant schizophrenia : a large-scale randomized-controlled trial in women of child-bearing age. 2014;(February):1–8. Available from: http://dx.doi.org/10.1038/mp.2014.33
Ravani DB, Pantovi MM, Milovanovi DR, Slavica Đ, Janji V, Risti D, et al. LONG-TERM EFFICACY OF ELECTROCONVULSIVE THERAPY COMBINED WITH DIFFERENT ANTIPSYCHOTIC DRUGS IN PREVIOUSLY RESISTANT SHIZOPHRENIA. 2009;21(2):179–86.
Flamarique I, Castro-fornieles J, Juan Þ, Garrido M, Serna E De, Pons ÞA, et al. Electroconvulsive Therapy and Clozapine in Adolescents With Schizophrenia Spectrum Disorders. 2012;32(6):756–66.
